2025
Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab
Foss F, Kim Y, Scarisbrick J, Akilov O, Ristuccia R, Dwyer K, Wu W, Bagot M. Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab. Journal Of Dermatological Treatment 2025, 36: 2438794. PMID: 39894454, DOI: 10.1080/09546634.2024.2438794.Peer-Reviewed Original ResearchConceptsMogamulizumab-associated rashConcomitant steroid useSezary syndromeAdvanced diseaseMycosis fungoidesSteroid useResponse to mogamulizumabProportion of patientsPercentage of patientsTreatment of patientsConcomitant steroidsRelapsed/refractory patientsLong-term responseMogamulizumabNext treatmentPatient characteristicsPatientsLymphopeniaVorinostatPatient responseFungoidesPFSMycosisSyndromeTreatment
2024
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Shroff R, King G, Colby S, Scott A, Borad M, Goff L, Matin K, Mahipal A, Kalyan A, Javle M, Dika I, Tan B, Cheema P, Patel A, Iyer R, Kelley R, Thumar J, El-Khoueiry A, Guthrie K, Chiorean E, Hochster H, Philip P. SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers. Journal Of Clinical Oncology 2024, 43: 536-544. PMID: 39671534, PMCID: PMC11798714, DOI: 10.1200/jco-24-01383.Peer-Reviewed Original ResearchProgression-free survivalBiliary tract cancerAdvanced biliary tract cancerOverall survivalGallbladder carcinomaExtrahepatic cholangiocarcinomaIntrahepatic cholangiocarcinomaHazard ratioNab-paclitaxelMedian progression-free survivalMetastatic biliary tract cancerProgression-free survival benefitPhase III randomized trialGemcitabine-cisplatin regimenTrial of gemcitabineLocally advanced diseaseExploratory subset analysisDiagnosing BTCEvaluated gemcitabineMedian OSMetastatic diseaseAdvanced diseaseNo significant differenceSubset analysisGemcitabineGastric Cancer at a Nigerian Tertiary Referral Center: Experiences With Establishing an Institutional Cancer Registry
Yibrehu B, Mohammed T, Murthy S, Aderibigbe A, Daramola O, Arije O, Owoade I, Wuraola F, Olasehinde O, Betiku O, Folorunso S, Omoyiola O, Aderounmu A, Adisa A, Kingham P, Alatise O. Gastric Cancer at a Nigerian Tertiary Referral Center: Experiences With Establishing an Institutional Cancer Registry. Journal Of Surgical Oncology 2024 PMID: 39558548, DOI: 10.1002/jso.27993.Peer-Reviewed Original ResearchInstitutional cancer registryGastric cancerCancer RegistryTreatment modalitiesSuspected gastric cancerManagement of gastric cancerQuality of registry dataTertiary referral centerGastric cancer registryHigh-risk patientsDatabase of patientsGastric cancer databasePeriodic chart reviewMetastatic diseaseAdvanced diseaseReferral centerCancer DatabaseAvailability of robust dataMedian timeChart reviewFollow-upDeadly malignancyBlood workPatientsRegistry dataLong-Term Results of External Beam Radiation Therapy (RT) with or without Concurrent Chemotherapy in Loco-Regionally Advanced or Recurrent Differentiated Thyroid Cancer (DTC)
Choi J, Sherman E, Youssef I, Kang J, Zakeri K, Yu Y, Chen L, Shamseddine A, McBride S, Riaz N, Hung T, Wong W, Michel L, Dunn L, Ho A, Tuttle R, Morris L, Shaha A, Wong R, Lee N. Long-Term Results of External Beam Radiation Therapy (RT) with or without Concurrent Chemotherapy in Loco-Regionally Advanced or Recurrent Differentiated Thyroid Cancer (DTC). International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e743-e744. DOI: 10.1016/j.ijrobp.2024.07.1633.Peer-Reviewed Original ResearchResults of external beam radiation therapyLocoregional controlRadioactive iodine therapyOverall survivalMultivariate analysisIodine therapyAdvanced diseaseBackward stepwise Cox regressionExternal beam radiation therapyRecurrent differentiated thyroid cancerProton beam RTBeam radiation therapyIntensity-modulated RTSingle-institution experienceTreated with RTMedian follow-upKaplan-Meier methodDay of RTStepwise Cox regressionGroup of patientsLong-term resultsBeam RTLate toxicityNon-medullaryConcurrent chemotherapyIncidence and time to onset of immunotherapy-related adrenal insufficiency in the I-SPY2 trial.
Nanda R, Cohen R, Quandt Z, Basu A, Yau C, Chien A, Pusztai L, Han H, Stringer-Reasor E, Isaacs C, Hershman D, Shatsky R, Perlmutter J, Yee D, DeMichele A, van 't Veer L, Hylton N, Esserman L, Rugo H. Incidence and time to onset of immunotherapy-related adrenal insufficiency in the I-SPY2 trial. Journal Of Clinical Oncology 2024, 42: 584-584. DOI: 10.1200/jco.2024.42.16_suppl.584.Peer-Reviewed Original ResearchImmune-related adverse eventsImmune checkpoint inhibitorsEarly breast cancerIncidence of AIAdrenal insufficiencyI-SPY2Advanced diseaseBreast cancerRisk of immune-related adverse eventsHigh-risk early breast cancerImmune checkpoint inhibitor doseTriple-negative breast cancerAnti-LAG-3Approval of pembrolizumabEvaluate novel agentsICI-based therapyWeekly x 4Rate of adrenal insufficiencyPhase 2 trialI-SPY2 trialTime to onsetAge of ptsCheckpoint inhibitorsNeoadjuvant settingWeekly paclitaxelNCCN Guidelines® Insights: Merkel Cell Carcinoma, Version 1.2024.
Schmults C, Blitzblau R, Aasi S, Alam M, Amini A, Bibee K, Bolotin D, Bordeaux J, Chen P, Contreras C, DiMaio D, Donigan J, Farma J, Ghosh K, Harms K, Ho A, Lukens J, Manber S, Mark L, Medina T, Nehal K, Nghiem P, Olino K, Park S, Patel T, Puzanov I, Rich J, Sekulic A, Shaha A, Srivastava D, Thomas V, Tomblinson C, Venkat P, Xu Y, Yu S, Yusuf M, McCullough B, Espinosa S. NCCN Guidelines® Insights: Merkel Cell Carcinoma, Version 1.2024. Journal Of The National Comprehensive Cancer Network 2024, 22: e240002. PMID: 38244274, DOI: 10.6004/jnccn.2024.0002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsLocally advanced diseaseMerkel cell carcinomaAdvanced diseaseLocally advanced Merkel cell carcinomaAdvanced Merkel cell carcinomaNode negative statusSystemic therapy optionsIn-transit diseaseNCCN Guidelines InsightsCell carcinomaNCCN GuidelinesClinical stageDiagnostic workupTherapy optionsTreatment optionsNegative statusInstitutional reviewNCCNDiseaseGuidelinesOptionsCarcinomaWorkupPatientsPanel members
2023
Association between sociodemographic factors and diagnosis of lethal prostate cancer in early life
Smani S, Novosel M, Sutherland R, Jeong F, Jalfon M, Marks V, Rajwa P, Nolazco J, Washington S, Renzulli J, Sprenkle P, Kim I, Leapman M. Association between sociodemographic factors and diagnosis of lethal prostate cancer in early life. Urologic Oncology Seminars And Original Investigations 2023, 42: 28.e9-28.e20. PMID: 38161105, DOI: 10.1016/j.urolonc.2023.10.005.Peer-Reviewed Original ResearchLethal prostate cancerSociodemographic factorsAdvanced CaPAdvanced diseaseYounger patientsProstate cancerHigher oddsAdvanced stageProstate-specific antigen (PSA) screeningCharacteristics of patientsNational Cancer DatabaseRetrospective cohort studySubset of patientsPatient sociodemographic factorsMultivariable logistic regressionPatients' health insuranceHighest income quartileCohort studyAdvanced cancerAntigen screeningMean ageInsurance statusCancer DatabaseCaP screeningSociodemographic disparitiesUnderstanding health-related quality of life measures used in early-stage non-small cell lung cancer clinical trials: A review
Majem M, Basch E, Cella D, Garon E, Herbst R, Leighl N. Understanding health-related quality of life measures used in early-stage non-small cell lung cancer clinical trials: A review. Lung Cancer 2023, 187: 107419. PMID: 38070301, DOI: 10.1016/j.lungcan.2023.107419.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerEarly-stage diseaseHealth-related qualityClinical trialsEarly-stage non-small cell lung cancerTreatment-related adverse effectsAppropriate HRQoL instrumentNSCLC clinical trialsCell lung cancerLong-term treatmentLung cancer clinical trialsCancer clinical researchCancer clinical trialsAdjuvant treatmentAdvanced diseaseHRQOL assessmentTreatment landscapeDisease recurrenceHRQoL instrumentsLung cancerDisease progressionLife measuresHRQoLNarrative reviewHealthcare professionalsPembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence
Harrington K, Cohen E, Soulières D, Dinis J, Licitra L, Ahn M, Soria A, Machiels J, Mach N, Mehra R, Burtness B, Swaby R, Lin J, Ge J, Lerman N, Tourneau C. Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence. Oral Oncology 2023, 147: 106587. PMID: 37925894, DOI: 10.1016/j.oraloncology.2023.106587.Peer-Reviewed Original ResearchConceptsSubgroup analysisRecurrence patternsNeck squamous cell carcinomaDisease recurrence patternsPlatinum-containing treatmentSquamous cell carcinomaLonger OSProlonged OSAdvanced diseaseData cutoffDefinitive therapyMetastatic headDurable responsesHazard ratioDisease recurrenceMetastatic HNSCCTreatment armsCell carcinomaM diseaseInvestigator's choicePatientsPembrolizumabRecurrentOnly subgroupSubgroupsPredictive Biomarkers in Advanced Renal Cell Carcinoma
Shinder B, Kronstedt S, Hakimi A. Predictive Biomarkers in Advanced Renal Cell Carcinoma. 2023, 251-268. DOI: 10.1007/978-3-031-40901-1_11.ChaptersRenal cell carcinomaAdvanced renal cell carcinomaCell carcinomaPredictive biomarkersEra of treatment optionsCharacteristics of renal cell carcinomaPrediction of treatment responseOptimal therapeutic pathwayTargeted systemic therapyImmuno-oncology agentsRoutine clinical useSystemic therapyAdvanced diseaseClinical benefitTreatment responseTreatment optionsClinical useTherapeutic pathwaysCarcinomaPatientsBiomarkersMolecular characteristicsTherapyDefining the denominator for measuring quality of end-of-life care in children with cancer: Results of a nominal group technique.
Johnston E, Tefera R, Ananth P, Martinez I, Porter A, Snaman J, Thienprayoon R, Asch S, Bhatia S, O'Beirne R. Defining the denominator for measuring quality of end-of-life care in children with cancer: Results of a nominal group technique. JCO Oncology Practice 2023, 19: 227-227. DOI: 10.1200/op.2023.19.11_suppl.227.Peer-Reviewed Original ResearchEOL quality measuresPoor-prognosis cancerQuality of EOLSpecific treatment scenarioNominal group techniqueHigh-quality EOL carePediatric palliative carePediatric critical careQuality of endNon-Hispanic whitesNational Quality ForumClinical program developmentAdvanced diseasePalliative carePediatric oncologyEOL careCritical careLife careStage IIIHospice cliniciansCertain symptomsCancerQuality ForumLife quality measuresTreatment scenariosSociety for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
Pavlick A, Ariyan C, Buchbinder E, Davar D, Gibney G, Hamid O, Hieken T, Izar B, Johnson D, Kulkarni R, Luke J, Mitchell T, Mooradian M, Rubin K, Salama A, Shirai K, Taube J, Tawbi H, Tolley J, Valdueza C, Weiss S, Wong M, Sullivan R. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0. Journal For ImmunoTherapy Of Cancer 2023, 11: e006947. PMID: 37852736, PMCID: PMC10603365, DOI: 10.1136/jitc-2023-006947.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsClinical practice guidelinesCutaneous melanomaTreatment of melanomaPractice guidelinesProlongs recurrence-free survivalCancer clinical practice guidelinesCell death protein 1Metastatic cutaneous melanomaBispecific T cell engager (BiTE) therapyChemotherapy-resistant diseaseRecurrence-free survivalDeath protein 1Long-term followManagement of patientsSpecial patient populationsImmunotherapy of cancerConsensus-based recommendationsPossibility of cureUnique toxicity profileQuality of lifeIntratumoral immunotherapyNeoadjuvant strategiesAdvanced diseaseBrain metastasesPatritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3–Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3–Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial
Krop I, Masuda N, Mukohara T, Takahashi S, Nakayama T, Inoue K, Iwata H, Yamamoto Y, Alvarez R, Toyama T, Takahashi M, Osaki A, Saji S, Sagara Y, O'Shaughnessy J, Ohwada S, Koyama K, Inoue T, Li L, Patel P, Mostillo J, Tanaka Y, Sternberg D, Sellami D, Yonemori K. Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3–Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3–Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial. Journal Of Clinical Oncology 2023, 41: 5550-5560. PMID: 37801674, PMCID: PMC10730028, DOI: 10.1200/jco.23.00882.Peer-Reviewed Original ResearchConceptsTreatment-emergent adverse eventsHuman epidermal growth factor receptor 3Epidermal growth factor receptor 3Metastatic breast cancerGrowth factor receptor 3Breast cancerReceptor 3Dose expansionPrevious therapyClinical subtypesCommon treatment-emergent adverse eventsPhase I/II trialHER2-positive breast cancerTriple-negative breast cancerDose-escalation partDose-expansion partManageable safety profileAdvanced breast cancerEpidermal growth factor receptorAntibody-drug conjugatesGrowth factor receptorAdvanced diseaseHematologic toxicityII trialObjective responsePD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma
Wartewig T, Daniels J, Schulz M, Hameister E, Joshi A, Park J, Morrish E, Venkatasubramani A, Cernilogar F, van Heijster F, Hundshammer C, Schneider H, Konstantinidis F, Gabler J, Klement C, Kurniawan H, Law C, Lee Y, Choi S, Guitart J, Forne I, Giustinani J, Müschen M, Jain S, Weinstock D, Rad R, Ortonne N, Schilling F, Schotta G, Imhof A, Brenner D, Choi J, Ruland J. PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma. Nature Cancer 2023, 4: 1508-1525. PMID: 37723306, PMCID: PMC10597841, DOI: 10.1038/s43018-023-00635-7.Peer-Reviewed Original ResearchConceptsPD-1T-NHLAP-1 activityT-cell non-Hodgkin lymphomaImmune checkpoint receptor PD-1Cell non-Hodgkin lymphomaCheckpoint receptor PD-1Receptor PD-1Non-Hodgkin lymphomaT-cell lymphomaT-cell malignanciesPrimary patient samplesTractable mouse modelAdvanced diseaseInferior prognosisProtein-1 transcription factorT cellsCell lymphomaMouse modelCell malignanciesATP citrate lyase activityACLY inhibitionPatient samplesTumor suppressive mechanismKey tumor suppressorHRD signature and HRD genomic landscape of tumors from 896 patients with early-stage breast cancer (BC).
Jeon J, Chen K, Madison R, Schrock A, Sokol E, Levy M, Oxnard G, Huang R, Pusztai L. HRD signature and HRD genomic landscape of tumors from 896 patients with early-stage breast cancer (BC). Journal Of Clinical Oncology 2023, 41: 539-539. DOI: 10.1200/jco.2023.41.16_suppl.539.Peer-Reviewed Original ResearchEarly-stage breast cancerPrimary breast cancerEarly breast cancerBreast cancerStage IHR-/HER2HRR deficiencyPALB2 mutationsEarly-stage primary breast cancerPARP inhibitorsStage IV diseaseHormone receptor statusMonths of diagnosisPositive breast cancerHomologous recombination repairComprehensive genomic profilingHRD signaturesClinical trial dataHigh rateSEER studySomatic BRCAAdjuvant therapyAdvanced diseaseReceptor statusBC subtypesSurvival analysis of patients treated at oncology practices with more aggressive end-of-life practice patterns.
Canavan M, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Adelson K. Survival analysis of patients treated at oncology practices with more aggressive end-of-life practice patterns. Journal Of Clinical Oncology 2023, 41: 6562-6562. DOI: 10.1200/jco.2023.41.16_suppl.6562.Peer-Reviewed Original ResearchReal-world overall survivalSystemic anticancer therapySurvival analysisNon-small cell lungCox proportional hazards modelPractice-level factorsRenal cell carcinomaProportional hazards modelCommon cancer typesDe-identified databaseElectronic health recordsAdvanced diseaseAdult patientsHazard ratioMetastatic diseaseMost patientsOverall survivalSurvival benefitSystemic treatmentAggressive endPrimary outcomeCell carcinomaCell lungPrimary exposureCancer patientsAssociation between sociodemographic factors and diagnosis of advanced prostate cancer in early life.
Smani S, Novosel M, Jeong F, Marks V, Sprenkle P, Leapman M. Association between sociodemographic factors and diagnosis of advanced prostate cancer in early life. Journal Of Clinical Oncology 2023, 41: 32-32. DOI: 10.1200/jco.2023.41.6_suppl.32.Peer-Reviewed Original ResearchAdvanced prostate cancerProstate cancerProstate cancer diagnosisSociodemographic factorsAdvanced diseaseYounger patientsNational Cancer DatabaseCancer diagnosisCharacteristics of patientsRetrospective cohort studySubset of patientsLethal prostate cancerMultivariable logistic regressionEarly prostate cancerHighest income quintileCohort studyAdvanced cancerInsurance statusCancer DatabaseSociodemographic disparitiesInclusion criteriaWhite raceGreater oddsPatientsAdvanced stageMelanoma in pregnancy
Czeyda-Pommersheim F, Kluger H, Langdon J, Menias C, VanBuren W, Leventhal J, Baumann R, Revzin M. Melanoma in pregnancy. Abdominal Radiology 2023, 48: 1740-1751. PMID: 36719425, DOI: 10.1007/s00261-022-03796-8.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsTreating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update
Bhatia A, Burtness B. Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update. Drugs 2023, 83: 217-248. PMID: 36645621, DOI: 10.1007/s40265-023-01835-2.Commentaries, Editorials and LettersConceptsNeck cancerRecurrent/metastatic settingImmune checkpoint inhibitor nivolumabNeck squamous cell carcinomaAge of immunotherapyLate stage HNSCCImmune checkpoint inhibitionPlatinum-containing chemotherapyFirst-line treatmentGrowth factor receptor overexpressionCheckpoint inhibitor nivolumabSquamous cell carcinomaEpidermal growth factor receptor (EGFR) overexpressionPathogenesis of HNSCCTreatment of patientsTreatment of HNSCCManagement of headMonoclonal antibody cetuximabCurative intentPalliative chemotherapyAdvanced diseaseInhibitor nivolumabLocoregional failureMetastatic settingMultimodality therapyAn autocrine signaling circuit in hepatic stellate cells underlies advanced fibrosis in nonalcoholic steatohepatitis
Wang S, Li K, Pickholz E, Dobie R, Matchett K, Henderson N, Carrico C, Driver I, Borch Jensen M, Chen L, Petitjean M, Bhattacharya D, Fiel M, Liu X, Kisseleva T, Alon U, Adler M, Medzhitov R, Friedman S. An autocrine signaling circuit in hepatic stellate cells underlies advanced fibrosis in nonalcoholic steatohepatitis. Science Translational Medicine 2023, 15: eadd3949. PMID: 36599008, PMCID: PMC10686705, DOI: 10.1126/scitranslmed.add3949.Peer-Reviewed Original ResearchConceptsHepatic stellate cellsAdvanced hepatic fibrosisNonalcoholic steatohepatitisAdvanced fibrosisHepatic fibrosisHSC activationStellate cellsMurine nonalcoholic steatohepatitisStage-specific therapyHuman nonalcoholic steatohepatitisHuman HSC activationNeurotrophic receptor tyrosine kinaseDrug targetsSingle-nucleus RNA sequencingAdvanced diseaseAntifibrotic efficacyAntifibrotic therapyFibrosisTherapeutic paradigmAutocrine interactionsPharmacological inhibitionReceptor tyrosine kinasesSteatohepatitisStrongest predictorTherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply